These findings emphasize the promising role of GALNT14-rs62139523 “A/G” genotype as a biomarker for predicting favorable outcomes in intermediate-stage CRC patients undergoing surgical resection followed by 5-FU-based adjuvant chemotherapy, with attention to specific subgroup characteristics. This evidence concerns the gene GALNT14 and colorectal carcinoma.